Brief: INmune Bio Reports Key Findings From Phase 2 MINDFuL Trial Of Xpro In Early Alzheimer’s Disease

Inmune Bio

30/06/2025 12:34

June 30 (Reuters) - INmune Bio Inc INMB.O:

INMUNE BIO REPORTS KEY FINDINGS FROM PHASE 2 MINDFUL TRIAL OF XPRO™ IN EARLY ALZHEIMER’S DISEASE

INMUNE BIO INC - PHASE 2 MINDFUL TRIAL DID NOT MEET PRIMARY COGNITIVE ENDPOINT IN MITT POPULATION

INMUNE BIO INC - XPRO TREATMENT WELL-TOLERATED AND SAFE IN HIGH RISK APOE4+/+ PATIENTS

INMUNE BIO INC - TO SCHEDULE END-OF-PHASE 2 MEETING WITH FDA IN Q4 2025

Source text: ID:nGNX1ZfvQ

Further company coverage: INMB.O

 ((Reuters.Briefs@thomsonreuters.com;))